Literature DB >> 14986176

Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2.

Wei Zhang1, Ting-Jun Hou, Xue Bin Qiao, Sun Huai, Xiao Jie Xu.   

Abstract

Here we report molecular dynamics (MD) and free energy perturbation (FEP) simulations applied to hydroxamate-matrix metalloproteinase-2 (MMP-2) complex systems. We have developed some new force field parameters for the hydroxamate functional group that were not included in the AMBER94 force field but were necessary in our simulations. For the representation of the active zinc center, a bonded model was adopted in which restrained electrostatic potential fitting (RESP) charges were used as the electrostatic representation of this model. Using the resulted bonded model, FEP simulations predict the relative binding free energy in good agreement with the experimental value. By analyzing the molecular dynamics (MD) trajectories of the two complex systems, we can provide an explanation of why one of the two inhibitors is favored over the other. The results provide a chemical insight into the interactions between inhibitor and enzyme, and can indicate changes in the inhibitor that would enhance inhibitor-enzyme interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986176     DOI: 10.1007/s00894-004-0181-1

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  16 in total

1.  Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase.

Authors:  S Toba; K V Damodaran; K M Merz
Journal:  J Med Chem       Date:  1999-04-08       Impact factor: 7.446

2.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

3.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.

Authors:  E Morgunova; A Tuuttila; U Bergmann; M Isupov; Y Lindqvist; G Schneider; K Tryggvason
Journal:  Science       Date:  1999-06-04       Impact factor: 47.728

4.  Matrix metalloproteinase inhibitors: a structure-activity study.

Authors:  D E Levy; F Lapierre; W Liang; W Ye; C W Lange; X Li; D Grobelny; M Casabonne; D Tyrrell; K Holme; A Nadzan; R E Galardy
Journal:  J Med Chem       Date:  1998-01-15       Impact factor: 7.446

5.  Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.

Authors:  L Chen; T J Rydel; F Gu; C M Dunaway; S Pikul; K M Dunham; B L Barnett
Journal:  J Mol Biol       Date:  1999-10-29       Impact factor: 5.469

6.  Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'.

Authors:  W Bode; F X Gomis-Rüth; W Stöckler
Journal:  FEBS Lett       Date:  1993-09-27       Impact factor: 4.124

7.  Wound repair-induced expression of a stromelysins is associated with the acquisition of a mesenchymal phenotype in human respiratory epithelial cells.

Authors:  A C Buisson; C Gilles; M Polette; J M Zahm; P Birembaut; J M Tournier
Journal:  Lab Invest       Date:  1996-03       Impact factor: 5.662

8.  Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself.

Authors:  B Lovejoy; A M Hassell; M A Luther; D Weigl; S R Jordan
Journal:  Biochemistry       Date:  1994-07-12       Impact factor: 3.162

9.  Human 92- and 72-kilodalton type IV collagenases are elastases.

Authors:  R M Senior; G L Griffin; C J Fliszar; S D Shapiro; G I Goldberg; H G Welgus
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

10.  Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.

Authors:  Tingjun Hou; Wei Zhang; Xiaojie Xu
Journal:  J Comput Aided Mol Des       Date:  2002-01       Impact factor: 3.686

View more
  8 in total

1.  Fundamental reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of heroin.

Authors:  Yan Qiao; Keli Han; Chang-Guo Zhan
Journal:  Biochemistry       Date:  2013-08-30       Impact factor: 3.162

2.  Fundamental reaction pathway for peptide metabolism by proteasome: insights from first-principles quantum mechanical/molecular mechanical free energy calculations.

Authors:  Donghui Wei; Lei Fang; Mingsheng Tang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2013-10-10       Impact factor: 2.991

3.  The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design.

Authors:  Haizhen Zhong; Melissa A Wees; Theresa D Faure; Carol Carrillo; Jack Arbiser; J Phillip Bowen
Journal:  ACS Med Chem Lett       Date:  2011-03-29       Impact factor: 4.345

4.  Fundamental reaction pathway and free energy profile for inhibition of proteasome by Epoxomicin.

Authors:  Donghui Wei; Beilei Lei; Mingsheng Tang; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2012-06-14       Impact factor: 15.419

5.  Modeling Structural Coordination and Ligand Binding in Zinc Proteins with a Polarizable Potential.

Authors:  Jiajing Zhang; Wei Yang; Jean-Philip Piquemal; Pengyu Ren
Journal:  J Chem Theory Comput       Date:  2012-01-02       Impact factor: 6.006

6.  Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants.

Authors:  Yongmei Pan; Daquan Gao; Wenchao Yang; Hoon Cho; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2007-10-10       Impact factor: 15.419

7.  Reaction pathways and free energy profiles for cholinesterase-catalyzed hydrolysis of 6-monoacetylmorphine.

Authors:  Yan Qiao; Keli Han; Chang-Guo Zhan
Journal:  Org Biomol Chem       Date:  2014-04-14       Impact factor: 3.876

8.  Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase.

Authors:  Wenchao Yang; Yongmei Pan; Fang Zheng; Hoon Cho; Hsin-Hsiung Tai; Chang-Guo Zhan
Journal:  Biophys J       Date:  2009-03-04       Impact factor: 4.033

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.